BackExagen Overview
Exagen Inc

Exagen Target Price

Where could XGN trade next? Consensus target price: $8.

Get informed when a big investor buys or sells

+ Follow

Share Price

$7.6

Average Target Price

$8.005.3% upside

2 analysts in the last 4 months

High: $8 | Low: $8

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-06-24Roth Capital$85.3% upsideOpen
2026-05-12BTIG$85.3% upsideOpen
2026-04-20Canaccord Genuity$85.3% upsideOpen
2026-03-11UBS$1031.6% upsideOpen
2026-03-10BTIGMark Massaro$918.4% upsideOpen
2026-02-17BTIGMark Massaro$1031.6% upsideOpen
2025-10-27Canaccord Genuity$1597.4% upsideOpen
2025-10-14KeyBanc$1597.4% upsideOpen
2025-07-30Cantor Fitzgerald$1031.6% upsideOpen
2025-07-29KeyBanc$1257.9% upsideOpen
2024-11-12BTIGMark Massaro$534.2% downsideOpen
2024-05-14Canaccord GenuityKyle Mikson$534.2% downsideOpen
2022-11-17BTIG$77.9% downsideOpen

Exagen (XGN) FAQ

Exagen (XGN) currently reports a target price of $8. Use the charts on this page to explore Exagen's target price history and peer comparisons.

Analysts' average 12-month price target for Exagen is $8, about 5.3% upside from the current share price of $7.6. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $8, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Exagen, and consider following XGN for alerts when major investors trade the stock.

Exagen is classified in the Healthcare sector. On target price, it currently shows $8. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XGN with unrelated industries.